Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduction of post-traumatic systemic inflammatory response by Phlogenzym in total hip replacement
2016-003078-41Phase 3Terminated
- Sponsor
- Mucos Pharma
- Start
- Sep 2016
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of trypsin + bromelain + rutoside in osteoarthritis (OA), hip osteoarthritis and post-operative inflammation, sponsored by Mucos Pharma. Primary endpoint: C-reactive protein in serum (AUC Day 1–7). Started Sep 2016; status: terminated.
02
Drugs
trypsin + bromelain + rutoside
03
Conditions
osteoarthritis (OA)hip osteoarthritispost-operative inflammation
Beyond the preview
Go deeper on 2016-003078-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003078-41.